The increased demand for targeted therapeutics has prompted oncology drug developers to uncover innovative solutions to new challenges. Fueled by an explosion of information about the biological underpinnings of cancer, now is a time of unprecedented opportunity in cancer drug development.
Listen as John Reddington, COO at Cambridge Biomedical, answers questions about how biomarkers and companion diagnostics are developed and the role they are playing in targeted oncology drug development. He also talks about some of the regulatory issues and commercialization challenges associated with biomarker development and offers advice on how to deal with them.
Listen To Interview